BCDA
Price:
$2
Market Cap:
$9.17M
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscl...[Read more]
Industry
Biotechnology
IPO Date
1996-11-13
Stock Exchange
NASDAQ
Ticker
BCDA
According to BioCardia, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 5.28M. This represents a change of -40.75% compared to the average of 8.92M of the last 4 quarters.
The mean historical Enterprise Value of BioCardia, Inc. over the last ten years is 29.21M. The current 5.28M Enterprise Value has changed 1.71% with respect to the historical average. Over the past ten years (40 quarters), BCDA's Enterprise Value was at its highest in in the December 2016 quarter at 351.21M. The Enterprise Value was at its lowest in in the September 2015 quarter at -12284697.60.
Average
29.21M
Median
19.07M
Minimum
-6669505.30
Maximum
87.14M
Discovering the peaks and valleys of BioCardia, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 67.79%
Maximum Annual Enterprise Value = 87.14M
Minimum Annual Increase = -1406.60%
Minimum Annual Enterprise Value = -6669505.30
Year | Enterprise Value | Change |
---|---|---|
2023 | 14.28M | -54.40% |
2022 | 31.30M | 43.49% |
2021 | 21.82M | 53.45% |
2020 | 14.22M | -12.93% |
2019 | 16.33M | -59.88% |
2018 | 40.70M | -47.14% |
2017 | 76.99M | -11.65% |
2016 | 87.14M | -1406.60% |
2015 | -6669505.30 | 67.79% |
2014 | -3975025.20 | -66.44% |
The current Enterprise Value of BioCardia, Inc. (BCDA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
22.47M
5-year avg
19.59M
10-year avg
29.21M
BioCardia, Inc.’s Enterprise Value is less than Aerovate Therapeutics, Inc. (44.50M), less than Adagene Inc. (11.00M), less than Acrivon Therapeutics, Inc. Common Stock (154.58M), less than Rezolute, Inc. (247.14M), less than AN2 Therapeutics, Inc. (7.13M), less than ZIVO Bioscience, Inc. (78.24M), less than Theseus Pharmaceuticals, Inc. (138.26M), less than Erasca, Inc. (710.66M), less than Forte Biosciences, Inc. (12.44M), greater than Applied Molecular Transport Inc. (-5743713.00), less than ABVC BioPharma, Inc. (8.81M), greater than Indaptus Therapeutics, Inc. (3.65M), greater than Pasithea Therapeutics Corp. (-6092141.00), less than Better Therapeutics, Inc. (7.71M), less than Anebulo Pharmaceuticals, Inc. (40.61M), less than Mineralys Therapeutics, Inc. (539.76M), less than NervGen Pharma Corp. (197.78M), greater than Protagenic Therapeutics, Inc. (2.29M), less than Miromatrix Medical Inc. (90.06M),
Company | Enterprise Value | Market cap |
---|---|---|
44.50M | $75.07M | |
11.00M | $85.89M | |
154.58M | $193.98M | |
247.14M | $255.53M | |
7.13M | $40.64M | |
78.24M | $78.37M | |
138.26M | $181.50M | |
710.66M | $726.61M | |
12.44M | $28.80M | |
-5743713.00 | $11.01M | |
8.81M | $6.62M | |
3.65M | $10.92M | |
-6092141.00 | $3.27M | |
7.71M | $5.45K | |
40.61M | $42.01M | |
539.76M | $637.04M | |
197.78M | $152.57M | |
2.29M | $3.34M | |
90.06M | $92.95M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioCardia, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BioCardia, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is BioCardia, Inc.'s Enterprise Value?
What is the highest Enterprise Value for BioCardia, Inc. (BCDA)?
What is the 3-year average Enterprise Value for BioCardia, Inc. (BCDA)?
What is the 5-year average Enterprise Value for BioCardia, Inc. (BCDA)?
How does the current Enterprise Value for BioCardia, Inc. (BCDA) compare to its historical average?